​

Funding Round

Series B - CRISPR Therapeutics

Series B - CRISPR Therapeutics

Investment Firm

Overview

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform.

Announced Date

Apr 30, 2015

Closed on Date

Apr 30, 2015

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

Celgene

Celgene

No designation

Vertex Pharmaceuticals

Vertex Pharmaceuticals

No designation

SR One

SR One

SR One is a early_stage_venture and late_stage_venture and post_ipo and private_equity and seed and venture firm.

Participant Investors

6

Investor Name
Participant InvestorVertex Pharmaceuticals
Participant InvestorCelgene
Participant InvestorAbingworth
Participant InvestorVersant Ventures
Participant InvestorNew Enterprise Associates

Round Details and Background

CRISPR Therapeutics raised $29000000 on 2015-04-30 in Series B

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform.

Company Funding History

6

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Dec 14, 2020
Grant - CRISPR Therapeutics
1-undefined
Feb 13, 2024
Post-IPO Equity - CRISPR Therapeutics
2-280.0M
Jun 24, 2016
Series B - CRISPR Therapeutics
4-38.0M
Apr 24, 2014
Series A - CRISPR Therapeutics
1-25.0M

Recent Activity

There is no recent news or activity for this profile.